Methylglyoxal‐glycated apolipoproteins A‐I and A‐ II are associated with new‐onset diabetes in individuals with prediabetes

Documenti analoghi

• Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
  di: Bertrand Cariou, et al.
  Pubblicazione: (2025)
• Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
  di: Sarra Smati, et al.
  Pubblicazione: (2024)
• A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes
  di: Olivier Bourron, et al.
  Pubblicazione: (2024)
• Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
  di: Johnny T. K. Cheung, et al.
  Pubblicazione: (2024)
• Relationship of high‐density lipoprotein subfractions and apolipoprotein A‐I with fat in the pancreas
  di: Yutong Liu, et al.
  Pubblicazione: (2024)